Hyperpigmentation is one of the most common concerns in aesthetic medicine. Dark spots that appear after summer, melasma that intensifies during pregnancy or menopause, post-inflammatory pigmentation following acne or aggressive treatments. They all share a common root: the overactivation of melanogenesis, the process by which melanocytes produce melanin in an uncontrolled manner.

Tranexamic acid has gone from being a hemostatic agent used in surgery to becoming one of the most promising actives for managing pigmentation. But as with everything in aesthetic medicine, it is not a universal solution: it requires correct indication, intelligent combination, and above all, medical judgment to avoid creating false expectations.

What is tranexamic acid and how does it work on the skin?

Tranexamic acid is a synthetic derivative of the amino acid lysine. Originally developed to stop bleeding by inhibiting plasmin, its dermatological use emerged as a secondary finding: patients treated with this agent showed significant reduction in hyperpigmented spots.

On the skin, its mechanism of action is multi-target:

• It inhibits the conversion of plasminogen to plasmin in keratinocytes, reducing the release of pro-pigmenting factors such as prostaglandin E2.
• It decreases tyrosinase activity, the key enzyme in melanin synthesis.
• It reduces the transport of melanin from melanocytes to upper epidermal cells.
• It modulates the vascular response associated with certain types of melasma, especially mixed and vascular variants.

This multi-channel mechanism makes it particularly useful for forms of pigmentation that do not respond to classical depigmenting agents such as hydroquinone, kojic acid, or vitamin C alone.

Why melasma is difficult to treat (and why tranexamic acid changes the approach)

Melasma is not a simple spot. It is a chronic and recurrent condition in which melanocytes are permanently hyperactive, conditioned by genetic, hormonal, and environmental factors. Any stimulus — sun, heat, inflammation, hormonal changes — can reactivate pigmentation even after successful treatment.

Traditional approaches (hydroquinone, aggressive peels, lasers) focus on destroying already-formed melanin. The problem is that thermal or chemical aggression can paradoxically worsen melasma through post-inflammatory hyperpigmentation, a phenomenon known as treatment-induced melasma.

Tranexamic acid operates from a different logic: instead of attacking produced melanin, it modulates the signals that trigger its manufacture. This makes it safer for sensitive skin and high phototypes (III-V), where the risk of post-inflammatory hyperpigmentation is greater.

How it is applied: topical, oral, or injectable

1. Topical formulation

The most accessible form is topical tranexamic acid, in concentrations of 2% to 5%. It comes in serums, creams, or combinations with other actives (niacinamide, kojic acid, vitamin C). Its efficacy is gradual: the first visible changes appear between 6 and 12 weeks of continuous use, always accompanied by strict sun protection.

2. Oral route (under medical prescription)

Oral tranexamic acid, in low doses (250-500 mg/day), is reserved for moderate to severe melasma that does not respond to topical treatment. Its use requires medical supervision because it can have contraindications (history of thrombosis, use of hormonal contraceptives, clotting disorders). In selected patients, improvement is significant, but it is always part of a comprehensive protocol, not self-medication.

3. Mesotherapy and microneedling

Intradermal administration via mesotherapy or microneedling allows the active to be concentrated in the pigmented area with minimal tissue aggression. This intermediate route is especially useful for localized spots and post-inflammatory pigmentation, combining the potency of the active with a favorable safety profile for reactive skin.

The Skin Esthetic approach: barrier first, depigmentation after

At Skin Esthetic del Levante we apply a guiding principle: the skin must be prepared before addressing pigmentation. If the barrier function is compromised, any depigmenting active can cause irritation that, instead of improving, worsens the problem. That is why our protocol includes:

• Assessment of phototype and melasma type (epidermal, dermal, or mixed) using Wood’s lamp examination.
• Repair of the skin barrier for 2-4 weeks before depigmenting treatment.
• Combination of tranexamic acid with niacinamide, phytic acid, or vitamin C depending on each patient’s profile.
• SPF 50+ sun protection as a non-negotiable pillar, without which no pigmentation treatment is sustainable.
• Periodic reviews: melasma is chronic and requires follow-up, not one-off treatments.

Not everything that can be done should be done. An aggressive laser on skin with dermal melasma can produce more pigmentation than it aims to eliminate. Medical judgment consists of choosing the right tool for the right problem at the right time.

When to consult a professional

If you have spots that appeared after summer, after pregnancy, or that are progressively intensifying, a medical assessment is the first step. Not all spots are melasma: solar dermatitis, post-inflammatory pigmentation, solar lentigines, and other skin conditions have different approaches. Self-diagnosing and self-medicating with depigmenting agents can worsen the condition.

Skin does not need haste, it needs judgment. Depigmentation is a process of months, not days, and the most lasting results are those built on a solid foundation: a healthy barrier, rigorous sun protection, and a plan adapted to your skin type.